Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07059923
Recruiting Observational

Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

NCT07059923 · tracked via the Priya Life Science China tracker
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Observational
Started
2025-07
Last updated
2025-07-11

Condition(s) studied

Lung Cancer (Diagnosis)

Study summary

CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026; 2. Aged \> 18 years old; 3. At least one CT scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than lung cancer; 4. Unclear pathological diagnosis.

Primary outcome measure(s)

  • Progression-free survival — 1 year
  • disease-free survival — 1 year
  • overall survival — 1 year

Trial sites (1)

FacilityCityRegionStatus
Union Hospital，Tongji Medical College，Huazhong University of Science and Technology Wuhan Hubei Recruiting

More Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials in China

Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors Recruiting
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus Starting soon
Pulse Wave vs. Saline Contrast EIT for Pulmonary Perfusion in ARDS Recruiting
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE Recruiting
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Recruiting

Other trials for the same condition

Acupressure for Cough in Lung Cancer Survivors Recruiting
Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer Recruiting
Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules Recruiting
Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules Starting soon
The Effect of Semi-recumbent Position on Hypoxemia After Lung Segment/Lobe Surgery Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07059923 on ClinicalTrials.gov ↗ ← All trials in China